A single dose of the DENV-1 candidate vaccine rDEN1δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial

Anna P Durbin, Stephen S. Whitehead, Donna Shaffer, Dan Elwood, Kimberli Wanionek, Bhagvanji Thumar, Joseph E. Blaney, Brian R. Murphy, Alexander C. Schmidt

Research output: Contribution to journalArticle

Abstract

Dengue is an emerging infectious disease that has become the most important arboviral infection worldwide. There are four serotypes of dengue virus, DENV-1, DENV-2, DENV-3, and DENV-4, each capable of causing the full spectrum of disease. rDEN1Δ30 is a live attenuated investigational vaccine for the prevention of DENV-1 illness and is also a component of an investigational tetravalent DENV vaccine currently in Phase I evaluation. A single subcutaneous dose of rDEN1Δ30 was previously shown to be safe and immunogenic in healthy adults. In the current randomized placebo-controlled trial, 60 healthy flavivirus-naive adults were randomized to receive 2 doses of rDEN1Δ30 (N = 50) or placebo (N = 10), either on study days 0 and 120 (cohort 1) or 0 and 180 (cohort 2). We sought to evaluate the safety and immunogenicity of this candidate vaccine in 50 additional vaccinees and to test whether the humoral immune response could be boosted by a second dose administered 4 or 6 months after the first dose. The first dose of vaccine was well tolerated, infected 47/50 vaccinees and induced seroconversion in 46/50 vaccinees. Irrespective of dosing interval, the second dose of vaccine was also well tolerated but did not induce any detectable viremia or ≥4-fold rise in serum neutralizing antibody titer.Only five subjects had an anamnestic antibody response detectable by ELISA following a second dose of vaccine, demonstrating that the vaccine induced sterilizing humoral immunity in most vaccinees for at least six months following primary vaccination.The promising safety and immunogenicity profile of this vaccine confirms its suitability for inclusion in a tetravalent dengue vaccine.

Original languageEnglish (US)
Article numbere1267
JournalPLoS Neglected Tropical Diseases
Volume5
Issue number8
DOIs
StatePublished - Aug 2011

Fingerprint

Vaccines
Humoral Immunity
Dengue Vaccines
Placebos
Emerging Communicable Diseases
Safety
Flavivirus
Attenuated Vaccines
Dengue Virus
Dengue
Viremia
Neutralizing Antibodies
Antibody Formation
Vaccination
Randomized Controlled Trials
Enzyme-Linked Immunosorbent Assay
Infection
Serum
Vaccine Immunogenicity

ASJC Scopus subject areas

  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

A single dose of the DENV-1 candidate vaccine rDEN1δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial. / Durbin, Anna P; Whitehead, Stephen S.; Shaffer, Donna; Elwood, Dan; Wanionek, Kimberli; Thumar, Bhagvanji; Blaney, Joseph E.; Murphy, Brian R.; Schmidt, Alexander C.

In: PLoS Neglected Tropical Diseases, Vol. 5, No. 8, e1267, 08.2011.

Research output: Contribution to journalArticle

Durbin, Anna P ; Whitehead, Stephen S. ; Shaffer, Donna ; Elwood, Dan ; Wanionek, Kimberli ; Thumar, Bhagvanji ; Blaney, Joseph E. ; Murphy, Brian R. ; Schmidt, Alexander C. / A single dose of the DENV-1 candidate vaccine rDEN1δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial. In: PLoS Neglected Tropical Diseases. 2011 ; Vol. 5, No. 8.
@article{dbc6c3da13a840b5a5b91346a1454a4f,
title = "A single dose of the DENV-1 candidate vaccine rDEN1δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial",
abstract = "Dengue is an emerging infectious disease that has become the most important arboviral infection worldwide. There are four serotypes of dengue virus, DENV-1, DENV-2, DENV-3, and DENV-4, each capable of causing the full spectrum of disease. rDEN1Δ30 is a live attenuated investigational vaccine for the prevention of DENV-1 illness and is also a component of an investigational tetravalent DENV vaccine currently in Phase I evaluation. A single subcutaneous dose of rDEN1Δ30 was previously shown to be safe and immunogenic in healthy adults. In the current randomized placebo-controlled trial, 60 healthy flavivirus-naive adults were randomized to receive 2 doses of rDEN1Δ30 (N = 50) or placebo (N = 10), either on study days 0 and 120 (cohort 1) or 0 and 180 (cohort 2). We sought to evaluate the safety and immunogenicity of this candidate vaccine in 50 additional vaccinees and to test whether the humoral immune response could be boosted by a second dose administered 4 or 6 months after the first dose. The first dose of vaccine was well tolerated, infected 47/50 vaccinees and induced seroconversion in 46/50 vaccinees. Irrespective of dosing interval, the second dose of vaccine was also well tolerated but did not induce any detectable viremia or ≥4-fold rise in serum neutralizing antibody titer.Only five subjects had an anamnestic antibody response detectable by ELISA following a second dose of vaccine, demonstrating that the vaccine induced sterilizing humoral immunity in most vaccinees for at least six months following primary vaccination.The promising safety and immunogenicity profile of this vaccine confirms its suitability for inclusion in a tetravalent dengue vaccine.",
author = "Durbin, {Anna P} and Whitehead, {Stephen S.} and Donna Shaffer and Dan Elwood and Kimberli Wanionek and Bhagvanji Thumar and Blaney, {Joseph E.} and Murphy, {Brian R.} and Schmidt, {Alexander C.}",
year = "2011",
month = "8",
doi = "10.1371/journal.pntd.0001267",
language = "English (US)",
volume = "5",
journal = "PLoS Neglected Tropical Diseases",
issn = "1935-2727",
publisher = "Public Library of Science",
number = "8",

}

TY - JOUR

T1 - A single dose of the DENV-1 candidate vaccine rDEN1δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial

AU - Durbin, Anna P

AU - Whitehead, Stephen S.

AU - Shaffer, Donna

AU - Elwood, Dan

AU - Wanionek, Kimberli

AU - Thumar, Bhagvanji

AU - Blaney, Joseph E.

AU - Murphy, Brian R.

AU - Schmidt, Alexander C.

PY - 2011/8

Y1 - 2011/8

N2 - Dengue is an emerging infectious disease that has become the most important arboviral infection worldwide. There are four serotypes of dengue virus, DENV-1, DENV-2, DENV-3, and DENV-4, each capable of causing the full spectrum of disease. rDEN1Δ30 is a live attenuated investigational vaccine for the prevention of DENV-1 illness and is also a component of an investigational tetravalent DENV vaccine currently in Phase I evaluation. A single subcutaneous dose of rDEN1Δ30 was previously shown to be safe and immunogenic in healthy adults. In the current randomized placebo-controlled trial, 60 healthy flavivirus-naive adults were randomized to receive 2 doses of rDEN1Δ30 (N = 50) or placebo (N = 10), either on study days 0 and 120 (cohort 1) or 0 and 180 (cohort 2). We sought to evaluate the safety and immunogenicity of this candidate vaccine in 50 additional vaccinees and to test whether the humoral immune response could be boosted by a second dose administered 4 or 6 months after the first dose. The first dose of vaccine was well tolerated, infected 47/50 vaccinees and induced seroconversion in 46/50 vaccinees. Irrespective of dosing interval, the second dose of vaccine was also well tolerated but did not induce any detectable viremia or ≥4-fold rise in serum neutralizing antibody titer.Only five subjects had an anamnestic antibody response detectable by ELISA following a second dose of vaccine, demonstrating that the vaccine induced sterilizing humoral immunity in most vaccinees for at least six months following primary vaccination.The promising safety and immunogenicity profile of this vaccine confirms its suitability for inclusion in a tetravalent dengue vaccine.

AB - Dengue is an emerging infectious disease that has become the most important arboviral infection worldwide. There are four serotypes of dengue virus, DENV-1, DENV-2, DENV-3, and DENV-4, each capable of causing the full spectrum of disease. rDEN1Δ30 is a live attenuated investigational vaccine for the prevention of DENV-1 illness and is also a component of an investigational tetravalent DENV vaccine currently in Phase I evaluation. A single subcutaneous dose of rDEN1Δ30 was previously shown to be safe and immunogenic in healthy adults. In the current randomized placebo-controlled trial, 60 healthy flavivirus-naive adults were randomized to receive 2 doses of rDEN1Δ30 (N = 50) or placebo (N = 10), either on study days 0 and 120 (cohort 1) or 0 and 180 (cohort 2). We sought to evaluate the safety and immunogenicity of this candidate vaccine in 50 additional vaccinees and to test whether the humoral immune response could be boosted by a second dose administered 4 or 6 months after the first dose. The first dose of vaccine was well tolerated, infected 47/50 vaccinees and induced seroconversion in 46/50 vaccinees. Irrespective of dosing interval, the second dose of vaccine was also well tolerated but did not induce any detectable viremia or ≥4-fold rise in serum neutralizing antibody titer.Only five subjects had an anamnestic antibody response detectable by ELISA following a second dose of vaccine, demonstrating that the vaccine induced sterilizing humoral immunity in most vaccinees for at least six months following primary vaccination.The promising safety and immunogenicity profile of this vaccine confirms its suitability for inclusion in a tetravalent dengue vaccine.

UR - http://www.scopus.com/inward/record.url?scp=80052416162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052416162&partnerID=8YFLogxK

U2 - 10.1371/journal.pntd.0001267

DO - 10.1371/journal.pntd.0001267

M3 - Article

C2 - 21829748

AN - SCOPUS:80052416162

VL - 5

JO - PLoS Neglected Tropical Diseases

JF - PLoS Neglected Tropical Diseases

SN - 1935-2727

IS - 8

M1 - e1267

ER -